Pharma

Cipla Ltd

CIPLA · NSE · INE059A01026
——consolidatedstandalone
Sentiment27 · Fear
Extreme FearFearNeutralGreedExtreme Greed
Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE11.8%
ROCE14.8%
ROE11.8%
1Y Return-7.17%
Avg. Volume0.7M

Price Chart

1,5841,4861,3881,2901,19247.7L95.4LOct 2025Nov 2025Dec 2025Feb 2026Mar 2026Apr 2026May 2026Jul 2026Oct 2026

About

Cipla Ltd is a Pharma company listed on NSE.

Pharma

Technicals

Free account

Technicals

Create a free account to view momentum, moving averages, and delivery signals.

Register free

Quant

Premium

Quant metrics

Upgrade to view volatility, drawdown, factor, and risk metrics.

Upgrade

Key Ratios

Market Cap—
Current Price—
52W High / Low—
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE11.8%
1Y Return-7.17%
Day Change—

Profit & Loss

ConsolidatedStandalone
Profit and loss statement
PeriodTTMFY26FY25FY24FY23FY22FY21FY20FY19FY18FY17FY16FY15
Sales₹28,324 Cr₹28,163 Cr₹27,548 Cr
Expenses₹23,027 Cr₹22,280 Cr₹20,420 Cr
Operating Profit₹5,297 Cr₹5,883 Cr₹7,128 Cr
OPM %19.0%21.0%26.0%
Other Income₹558 Cr₹606 Cr₹862 Cr
Depreciation₹1,262 Cr₹1,211 Cr₹1,107 Cr
Interest₹57 Cr₹54 Cr₹62 Cr
Profit Before Tax₹4,536 Cr₹5,224 Cr₹6,821 Cr
Tax₹1,180 Cr₹1,362 Cr₹1,552 Cr
Net Profit₹3,356 Cr₹3,862 Cr₹5,269 Cr
EPS (₹)41.748.065.3
Dividend Payout %—27%25%
Financial history locked

Register free to see 10 more years.

Register free

Quarterly Results

Quarterly results
QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
Sales₹7,119 Cr₹6,541 Cr₹7,074 Cr₹7,589 Cr
Expenses₹5,927 Cr₹5,586 Cr₹5,819 Cr₹5,695 Cr
Operating Profit₹1,192 Cr₹955 Cr₹1,255 Cr₹1,895 Cr
OPM %17.0%15.0%18.0%25.0%
Depreciation₹304 Cr₹383 Cr₹278 Cr₹297 Cr
Interest₹17 Cr₹13 Cr₹14 Cr₹13 Cr
Net Profit₹786 Cr₹543 Cr₹674 Cr₹1,353 Cr
EPS (₹)9.86.98.416.7
Quarterly history locked

Register free to see 9 more quarters.

Register free

Balance Sheet

Balance sheet
PeriodFY26FY25FY24FY23FY22FY21FY20FY19FY18FY17FY16FY15
Liabilities
Equity Capital₹162 Cr₹162 Cr₹161 Cr
Reserves₹34,270 Cr₹31,032 Cr₹26,545 Cr
Borrowings₹614 Cr₹438 Cr₹559 Cr
Other Liabilities₹7,297 Cr₹5,702 Cr₹5,268 Cr
Total Liabilities₹42,343 Cr₹37,334 Cr₹32,533 Cr
Assets
Fixed Assets₹12,434 Cr₹10,006 Cr₹9,607 Cr
Investments₹8,223 Cr₹7,933 Cr₹5,449 Cr
Receivables———
Inventory———
Cash & Equivalents———
Other Assets₹19,643 Cr₹17,828 Cr₹16,323 Cr
Total Assets₹42,343 Cr₹37,334 Cr₹32,533 Cr
Balance sheet history locked

Register free to see 10 more years.

Register free

Cash Flow

Cash flow statement
PeriodOperatingInvestingFinancingNet Cash Flow
FY26₹3,940 Cr₹-2,234 Cr₹-1,234 Cr₹473 Cr
FY25₹5,005 Cr₹-3,682 Cr₹-1,293 Cr₹30 Cr
FY24₹4,134 Cr₹-2,982 Cr₹-1,200 Cr₹-49 Cr
FY23
FY22
FY21
FY20
FY19
FY18
FY17
FY16
FY15
Cash flow history locked

Register free to see 10 more years.

Register free

Peer Comparison

Peer comparison
CompanyM.CapP/EROE1Y Return
3B BlackBio Dx Ltd₹1,210 Cr21.4+20.2%+17.9%
Aarey Drugs & Pharmaceuticals Ltd₹353 Cr75.3+2.75%+59.84%
Aarti Drugs Ltd₹3,429 Cr18.0+13.37%+11.57%
Aarti Pharmalabs Ltd₹7,495 Cr35.2+8.51%+14.26%
Abbott India Ltd——+34.46%-7.16%

Mutual Fund Holdings

Free account

Mutual fund holdings

Create a free account to see institutional ownership snapshots.

Register free

Bulk & Block Deals

Free account

Bulk & block deals

Create a free account to view recent institutional deal activity.

Register free

Analyst Estimates

Free account

Analyst estimates

Create a free account to view analyst estimate summaries.

Register free

Latest News

2026-10-23USFDA Inspection At Invagen Manufacturing Facility In Hauppauge, Long Island, New York, USABSE Filing2026-07-25Cipla Ltd (BOM:500087) Q1 2027 Earnings Call Highlights: Strong Start with Record Revenue ...GuruFocus.com

Documents & Filings

rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.